Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 3/20 | 0.62 |
| ▸ | PRKCG | P05129 | 1/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.60 |
| ▸ | RORC | P51449 | 3/20 | 0.59 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13628224 | 1.00 | NT5E (0.62) | NT5EPRKCGTRPV1RORCPRKCD | |
| SCHEMBL12557842 | 0.93 | NT5E (0.61) | NT5EPRKCGTRPV1RORC | |
| SCHEMBL12557916 | 0.93 | RORC (0.67) | NT5EPRKCGTRPV1RORCPRKCD | |
| SCHEMBL13637672 | 0.89 | RORC (0.73) | NT5ETRPV1RORC | |
| SCHEMBL13628221 | 0.89 | RORC (0.73) | NT5ETRPV1RORC | |
| SCHEMBL12557898 | 0.89 | TRPV1 (0.60) | NT5EPRKCGTRPV1RORC | |
| SCHEMBL12557918 | 0.87 | PRKCG (0.61) | NT5EPRKCGRORCPRKCD | |
| SCHEMBL12557845 | 0.87 | PRKCG (0.69) | NT5EPRKCGTRPV1RORCPRKCD | |
| SCHEMBL9350734 | 0.86 | PRKCD (0.73) | NT5ERORCPRKCD | |
| SCHEMBL9130038 | 0.86 | PRKCD (0.73) | NT5ERORCPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MAVS, ZC3HAV1, EIF2AK2 | NT5E 304/4885PRKCG 3834/4885TRPV1 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.